Antimicrobial resistance caused 4.95 million deaths associated with AMR and 1.27 million deaths attributable to AMR in 2019. Vaccines can prevent a proportion of the AMR burden by preventing drug-sensitive and drug-resistant infections, reducing antibiotic use and reducing pathogen transmission and chances of developing resistance genes. Increasing evidence from observational and modelling studies show the impact of vaccines on AMR.
However, this evidence is yet to translate to policy and decision-making about which vaccines to develop, introduce so they effectively prevent AMR. This webinar will explore the mechanisms, evidence and value of vaccines in preventing AMR. A panel of experts will discuss what are the challenges to ensure that vaccines to prevent AMR are developed and widely used.
Scientists, product developers, regulators, policy makers, implementers and funders interested in the role of vaccines in preventing AMR
– The threat of AMR and ways through which vaccines can prevent it;
– Assessment of the value of vaccines in preventing AMR;
– Research priorities on vaccines and AMR;
– Development pipeline for vaccines against AMR priority pathogens;
– The role of vaccines in National Action Plans on AMR;
– Stories from the field: how vaccines were used in Zimbabwe to prevent AMR;
– Challenges and opportunities to ensure that vaccines against AMR are developed and used.
Registration on this page